CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 29 enrolled
Drug / intervention
Coffeedietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04827251
NCT04827251N/ACompleted
CompareCT.gov

Evaluation of the Effect of Espresso on Platelet Aggregability in Patients with Coronary Artery Disease

University of Sao Paulo·interventional·Posted Apr 1, 2021·Updated Feb 13, 2025

In Brief

A clinical study evaluating Coffee for Coronary Artery Disease. Completed, enrolled 29 participants across 1 site.

Detailed Summary

Discovered thousands of years ago, coffee is among the most consumed beverages in the world. The relationship between coffee and cardiovascular risk, more specifically coronary artery disease, is controversial. Platelet aggregation and its relationship with coffee is also controversial. The investigators propose this study to evaluate the relationship between coffee and platelet aggregability in patients with coronary artery disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesBrazil
CollaboratorsFundação de Amparo à Pesquisa do Estado de São Paulo

Timeline

N/ACompletedFinished
20222023202420252026
First PostedApr 1, 2021
Enrollment StartSep 1, 2022
Primary CompletionNov 25, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.3 years ago

Interventions

Coffeedietary

Participants will receive "Nespresso" coffee maker "Essenza" model. The coffee "Nespresso blend voluto" will be provided (caffeinated and decaffeinated). The patients will have to take four cups of espresso per day (three cups a day for patients aged 65 and over).